309 related articles for article (PubMed ID: 36203933)
1. The AMPK pathway in fatty liver disease.
Fang C; Pan J; Qu N; Lei Y; Han J; Zhang J; Han D
Front Physiol; 2022; 13():970292. PubMed ID: 36203933
[TBL] [Abstract][Full Text] [Related]
2. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.
Liu Y; Li Y; Wang J; Yang L; Yu X; Huang P; Song H; Zheng P
BMC Complement Med Ther; 2022 Aug; 22(1):213. PubMed ID: 35945571
[TBL] [Abstract][Full Text] [Related]
3. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
[TBL] [Abstract][Full Text] [Related]
4. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
5. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway.
Li R; Li Y; Yang X; Hu Y; Yu H; Li Y
J Transl Med; 2022 Jul; 20(1):341. PubMed ID: 35907871
[TBL] [Abstract][Full Text] [Related]
6. High-altitude chronic hypoxia ameliorates obesity-induced non-alcoholic fatty liver disease in mice by regulating mitochondrial and AMPK signaling.
Song K; Zhang Y; Ga Q; Bai Z; Ge RL
Life Sci; 2020 Jul; 252():117633. PubMed ID: 32289432
[TBL] [Abstract][Full Text] [Related]
7. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
8. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of E Se tea extracts against alcoholic fatty liver disease induced by high fat/alcohol diet: In vivo biological evaluation and molecular docking study.
Wang Y; Fan Z; Yang M; Wang Y; Cao J; Khan A; Liu Y; Cheng G
Phytomedicine; 2022 Jul; 101():154113. PubMed ID: 35490493
[TBL] [Abstract][Full Text] [Related]
10. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
11. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
12. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
[TBL] [Abstract][Full Text] [Related]
13. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway.
Chen K; Chen X; Xue H; Zhang P; Fang W; Chen X; Ling W
Food Funct; 2019 Feb; 10(2):814-823. PubMed ID: 30675881
[TBL] [Abstract][Full Text] [Related]
14. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
Fu D; Cui H; Zhang Y
Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
[TBL] [Abstract][Full Text] [Related]
15. Potential use of C-phycocyanin in non-alcoholic fatty liver disease.
Ma P; Huang R; Jiang J; Ding Y; Li T; Ou Y
Biochem Biophys Res Commun; 2020 Jun; 526(4):906-912. PubMed ID: 32279997
[TBL] [Abstract][Full Text] [Related]
16. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
17. Berbamine induced AMPK activation regulates mTOR/SREBP-1c axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells.
Sharma A; Anand SK; Singh N; Dwivedi UN; Kakkar P
Eur J Pharmacol; 2020 Sep; 882():173244. PubMed ID: 32526241
[TBL] [Abstract][Full Text] [Related]
18. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling.
Sheng D; Zhao S; Gao L; Zheng H; Liu W; Hou J; Jin Y; Ye F; Zhao Q; Li R; Zhao N; Zhang L; Han Z; Wei L
Cell Biosci; 2019; 9():77. PubMed ID: 31548878
[TBL] [Abstract][Full Text] [Related]
19. Astaxanthin Alleviates Nonalcoholic Fatty Liver Disease by Regulating the Intestinal Flora and Targeting the AMPK/Nrf2 Signal Axis.
Li Y; Liu J; Ye B; Cui Y; Geng R; Liu S; Zhang Y; Guo W; Fu S
J Agric Food Chem; 2022 Aug; 70(34):10620-10634. PubMed ID: 35973099
[TBL] [Abstract][Full Text] [Related]
20. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW
Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
